Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0QDCHN)
| ADC Name |
PRO1160
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
PRO1160; GEN1160
Click to Show/Hide
|
|||||
| Organization |
ProfoundBio (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD70 antibody
|
Antibody Info | ||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
T1000
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
sesutecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Follicular lymphoma |
1 Trials
|
|||||
| Diffuse large B-cell lymphoma |
1 Trials
|
|||||
| Mantle cell lymphoma |
1 Trials
|
|||||
| Nasopharyngeal cancer |
1 Trials
|
|||||
| Kidney cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have confirmed metastatic/unresectable RCC, NPC, or NHL (stage III/IV), be refractory to prior therapies, have ECOG 0-1, and measurable disease. Exclusions include previous anti-CD70 therapy, active CNS metastases (unless treated/stable), uncontrolled infections, HBV/HCV/HIV positivity, or recent strong CYP3A inhibitor use (dose escalation only).
Click to Show/Hide
|
||||
| Administration Dosage |
PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05721222 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL) | ||||
| Primary Endpoint |
Safety will be evaluated by assessing treatment-emergent adverse events (frequency, severity, and seriousness) and dose-limiting toxicities throughout the treatment period up to approximately 1 year.
|
||||
| Other Endpoint |
Efficacy measurements include objective response rate, disease control rate (assessed by RECIST v1.1 for solid tumors or Lugano 2014 for NHL), progression-free survival (analyzed up to 18 months), and duration of response (tracked until disease progression/withdrawal). Pharmacokinetic analysis will determine PRO1160's peak plasma concentration (Cmax).
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05721222 | Clinical Status | Phase 1/2 | ||
| Clinical Description | Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL). | ||||
References